Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Colorectal Cancer Therapeutics Market

ID: MRFR/HC/41734-HCR
200 Pages
Satyendra Maurya
Last Updated: April 06, 2026

Colorectal Cancer Therapeutics Market Research Report: Size, Share, Trend Analysis By Therapeutic Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery), By Drug Class (5-Fluorouracil, Oxaliplatin, Bevacizumab, Cetuximab, Regorafenib), By Route of Administration (Oral, Intravenous, Subcutaneous), By Patient Type (Adult, Pediatric, Geriatric) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Colorectal Cancer Therapeutics Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Therapeutic Type (USD Billion)
  49.     4.1.1 Chemotherapy
  50.     4.1.2 Targeted Therapy
  51.     4.1.3 Immunotherapy
  52.     4.1.4 Radiation Therapy
  53.     4.1.5 Surgery
  54.   4.2 Healthcare, BY Drug Class (USD Billion)
  55.     4.2.1 5-Fluorouracil
  56.     4.2.2 Oxaliplatin
  57.     4.2.3 Bevacizumab
  58.     4.2.4 Cetuximab
  59.     4.2.5 Regorafenib
  60.   4.3 Healthcare, BY Route of Administration (USD Billion)
  61.     4.3.1 Oral
  62.     4.3.2 Intravenous
  63.     4.3.3 Subcutaneous
  64.   4.4 Healthcare, BY Patient Type (USD Billion)
  65.     4.4.1 Adult
  66.     4.4.2 Pediatric
  67.     4.4.3 Geriatric
  68.   4.5 Healthcare, BY Region (USD Billion)
  69.     4.5.1 North America
  70.       4.5.1.1 US
  71.       4.5.1.2 Canada
  72.     4.5.2 Europe
  73.       4.5.2.1 Germany
  74.       4.5.2.2 UK
  75.       4.5.2.3 France
  76.       4.5.2.4 Russia
  77.       4.5.2.5 Italy
  78.       4.5.2.6 Spain
  79.       4.5.2.7 Rest of Europe
  80.     4.5.3 APAC
  81.       4.5.3.1 China
  82.       4.5.3.2 India
  83.       4.5.3.3 Japan
  84.       4.5.3.4 South Korea
  85.       4.5.3.5 Malaysia
  86.       4.5.3.6 Thailand
  87.       4.5.3.7 Indonesia
  88.       4.5.3.8 Rest of APAC
  89.     4.5.4 South America
  90.       4.5.4.1 Brazil
  91.       4.5.4.2 Mexico
  92.       4.5.4.3 Argentina
  93.       4.5.4.4 Rest of South America
  94.     4.5.5 MEA
  95.       4.5.5.1 GCC Countries
  96.       4.5.5.2 South Africa
  97.       4.5.5.3 Rest of MEA
  98. 5 SECTION V: COMPETITIVE ANALYSIS
  99.   5.1 Competitive Landscape
  100.     5.1.1 Overview
  101.     5.1.2 Competitive Analysis
  102.     5.1.3 Market share Analysis
  103.     5.1.4 Major Growth Strategy in the Healthcare
  104.     5.1.5 Competitive Benchmarking
  105.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  106.     5.1.7 Key developments and growth strategies
  107.       5.1.7.1 New Product Launch/Service Deployment
  108.       5.1.7.2 Merger & Acquisitions
  109.       5.1.7.3 Joint Ventures
  110.     5.1.8 Major Players Financial Matrix
  111.       5.1.8.1 Sales and Operating Income
  112.       5.1.8.2 Major Players R&D Expenditure. 2023
  113.   5.2 Company Profiles
  114.     5.2.1 Roche (CH)
  115.       5.2.1.1 Financial Overview
  116.       5.2.1.2 Products Offered
  117.       5.2.1.3 Key Developments
  118.       5.2.1.4 SWOT Analysis
  119.       5.2.1.5 Key Strategies
  120.     5.2.2 Merck (DE)
  121.       5.2.2.1 Financial Overview
  122.       5.2.2.2 Products Offered
  123.       5.2.2.3 Key Developments
  124.       5.2.2.4 SWOT Analysis
  125.       5.2.2.5 Key Strategies
  126.     5.2.3 Bristol-Myers Squibb (US)
  127.       5.2.3.1 Financial Overview
  128.       5.2.3.2 Products Offered
  129.       5.2.3.3 Key Developments
  130.       5.2.3.4 SWOT Analysis
  131.       5.2.3.5 Key Strategies
  132.     5.2.4 Amgen (US)
  133.       5.2.4.1 Financial Overview
  134.       5.2.4.2 Products Offered
  135.       5.2.4.3 Key Developments
  136.       5.2.4.4 SWOT Analysis
  137.       5.2.4.5 Key Strategies
  138.     5.2.5 Johnson & Johnson (US)
  139.       5.2.5.1 Financial Overview
  140.       5.2.5.2 Products Offered
  141.       5.2.5.3 Key Developments
  142.       5.2.5.4 SWOT Analysis
  143.       5.2.5.5 Key Strategies
  144.     5.2.6 Novartis (CH)
  145.       5.2.6.1 Financial Overview
  146.       5.2.6.2 Products Offered
  147.       5.2.6.3 Key Developments
  148.       5.2.6.4 SWOT Analysis
  149.       5.2.6.5 Key Strategies
  150.     5.2.7 Sanofi (FR)
  151.       5.2.7.1 Financial Overview
  152.       5.2.7.2 Products Offered
  153.       5.2.7.3 Key Developments
  154.       5.2.7.4 SWOT Analysis
  155.       5.2.7.5 Key Strategies
  156.     5.2.8 AstraZeneca (GB)
  157.       5.2.8.1 Financial Overview
  158.       5.2.8.2 Products Offered
  159.       5.2.8.3 Key Developments
  160.       5.2.8.4 SWOT Analysis
  161.       5.2.8.5 Key Strategies
  162.     5.2.9 Eli Lilly (US)
  163.       5.2.9.1 Financial Overview
  164.       5.2.9.2 Products Offered
  165.       5.2.9.3 Key Developments
  166.       5.2.9.4 SWOT Analysis
  167.       5.2.9.5 Key Strategies
  168.   5.3 Appendix
  169.     5.3.1 References
  170.     5.3.2 Related Reports
  171. 6 LIST OF FIGURES
  172.   6.1 MARKET SYNOPSIS
  173.   6.2 NORTH AMERICA MARKET ANALYSIS
  174.   6.3 US MARKET ANALYSIS BY THERAPEUTIC TYPE
  175.   6.4 US MARKET ANALYSIS BY DRUG CLASS
  176.   6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  177.   6.6 US MARKET ANALYSIS BY PATIENT TYPE
  178.   6.7 CANADA MARKET ANALYSIS BY THERAPEUTIC TYPE
  179.   6.8 CANADA MARKET ANALYSIS BY DRUG CLASS
  180.   6.9 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  181.   6.10 CANADA MARKET ANALYSIS BY PATIENT TYPE
  182.   6.11 EUROPE MARKET ANALYSIS
  183.   6.12 GERMANY MARKET ANALYSIS BY THERAPEUTIC TYPE
  184.   6.13 GERMANY MARKET ANALYSIS BY DRUG CLASS
  185.   6.14 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  186.   6.15 GERMANY MARKET ANALYSIS BY PATIENT TYPE
  187.   6.16 UK MARKET ANALYSIS BY THERAPEUTIC TYPE
  188.   6.17 UK MARKET ANALYSIS BY DRUG CLASS
  189.   6.18 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  190.   6.19 UK MARKET ANALYSIS BY PATIENT TYPE
  191.   6.20 FRANCE MARKET ANALYSIS BY THERAPEUTIC TYPE
  192.   6.21 FRANCE MARKET ANALYSIS BY DRUG CLASS
  193.   6.22 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  194.   6.23 FRANCE MARKET ANALYSIS BY PATIENT TYPE
  195.   6.24 RUSSIA MARKET ANALYSIS BY THERAPEUTIC TYPE
  196.   6.25 RUSSIA MARKET ANALYSIS BY DRUG CLASS
  197.   6.26 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  198.   6.27 RUSSIA MARKET ANALYSIS BY PATIENT TYPE
  199.   6.28 ITALY MARKET ANALYSIS BY THERAPEUTIC TYPE
  200.   6.29 ITALY MARKET ANALYSIS BY DRUG CLASS
  201.   6.30 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  202.   6.31 ITALY MARKET ANALYSIS BY PATIENT TYPE
  203.   6.32 SPAIN MARKET ANALYSIS BY THERAPEUTIC TYPE
  204.   6.33 SPAIN MARKET ANALYSIS BY DRUG CLASS
  205.   6.34 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  206.   6.35 SPAIN MARKET ANALYSIS BY PATIENT TYPE
  207.   6.36 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC TYPE
  208.   6.37 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS
  209.   6.38 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  210.   6.39 REST OF EUROPE MARKET ANALYSIS BY PATIENT TYPE
  211.   6.40 APAC MARKET ANALYSIS
  212.   6.41 CHINA MARKET ANALYSIS BY THERAPEUTIC TYPE
  213.   6.42 CHINA MARKET ANALYSIS BY DRUG CLASS
  214.   6.43 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  215.   6.44 CHINA MARKET ANALYSIS BY PATIENT TYPE
  216.   6.45 INDIA MARKET ANALYSIS BY THERAPEUTIC TYPE
  217.   6.46 INDIA MARKET ANALYSIS BY DRUG CLASS
  218.   6.47 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  219.   6.48 INDIA MARKET ANALYSIS BY PATIENT TYPE
  220.   6.49 JAPAN MARKET ANALYSIS BY THERAPEUTIC TYPE
  221.   6.50 JAPAN MARKET ANALYSIS BY DRUG CLASS
  222.   6.51 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  223.   6.52 JAPAN MARKET ANALYSIS BY PATIENT TYPE
  224.   6.53 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC TYPE
  225.   6.54 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS
  226.   6.55 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  227.   6.56 SOUTH KOREA MARKET ANALYSIS BY PATIENT TYPE
  228.   6.57 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC TYPE
  229.   6.58 MALAYSIA MARKET ANALYSIS BY DRUG CLASS
  230.   6.59 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  231.   6.60 MALAYSIA MARKET ANALYSIS BY PATIENT TYPE
  232.   6.61 THAILAND MARKET ANALYSIS BY THERAPEUTIC TYPE
  233.   6.62 THAILAND MARKET ANALYSIS BY DRUG CLASS
  234.   6.63 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  235.   6.64 THAILAND MARKET ANALYSIS BY PATIENT TYPE
  236.   6.65 INDONESIA MARKET ANALYSIS BY THERAPEUTIC TYPE
  237.   6.66 INDONESIA MARKET ANALYSIS BY DRUG CLASS
  238.   6.67 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  239.   6.68 INDONESIA MARKET ANALYSIS BY PATIENT TYPE
  240.   6.69 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC TYPE
  241.   6.70 REST OF APAC MARKET ANALYSIS BY DRUG CLASS
  242.   6.71 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  243.   6.72 REST OF APAC MARKET ANALYSIS BY PATIENT TYPE
  244.   6.73 SOUTH AMERICA MARKET ANALYSIS
  245.   6.74 BRAZIL MARKET ANALYSIS BY THERAPEUTIC TYPE
  246.   6.75 BRAZIL MARKET ANALYSIS BY DRUG CLASS
  247.   6.76 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  248.   6.77 BRAZIL MARKET ANALYSIS BY PATIENT TYPE
  249.   6.78 MEXICO MARKET ANALYSIS BY THERAPEUTIC TYPE
  250.   6.79 MEXICO MARKET ANALYSIS BY DRUG CLASS
  251.   6.80 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  252.   6.81 MEXICO MARKET ANALYSIS BY PATIENT TYPE
  253.   6.82 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC TYPE
  254.   6.83 ARGENTINA MARKET ANALYSIS BY DRUG CLASS
  255.   6.84 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  256.   6.85 ARGENTINA MARKET ANALYSIS BY PATIENT TYPE
  257.   6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC TYPE
  258.   6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS
  259.   6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  260.   6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT TYPE
  261.   6.90 MEA MARKET ANALYSIS
  262.   6.91 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC TYPE
  263.   6.92 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS
  264.   6.93 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  265.   6.94 GCC COUNTRIES MARKET ANALYSIS BY PATIENT TYPE
  266.   6.95 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC TYPE
  267.   6.96 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS
  268.   6.97 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  269.   6.98 SOUTH AFRICA MARKET ANALYSIS BY PATIENT TYPE
  270.   6.99 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC TYPE
  271.   6.100 REST OF MEA MARKET ANALYSIS BY DRUG CLASS
  272.   6.101 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
  273.   6.102 REST OF MEA MARKET ANALYSIS BY PATIENT TYPE
  274.   6.103 KEY BUYING CRITERIA OF HEALTHCARE
  275.   6.104 RESEARCH PROCESS OF MRFR
  276.   6.105 DRO ANALYSIS OF HEALTHCARE
  277.   6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  278.   6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  279.   6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
  280.   6.109 HEALTHCARE, BY THERAPEUTIC TYPE, 2024 (% SHARE)
  281.   6.110 HEALTHCARE, BY THERAPEUTIC TYPE, 2024 TO 2035 (USD Billion)
  282.   6.111 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE)
  283.   6.112 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion)
  284.   6.113 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
  285.   6.114 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
  286.   6.115 HEALTHCARE, BY PATIENT TYPE, 2024 (% SHARE)
  287.   6.116 HEALTHCARE, BY PATIENT TYPE, 2024 TO 2035 (USD Billion)
  288.   6.117 BENCHMARKING OF MAJOR COMPETITORS
  289. 7 LIST OF TABLES
  290.   7.1 LIST OF ASSUMPTIONS
  291.     7.1.1
  292.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  293.     7.2.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  294.     7.2.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  295.     7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  296.     7.2.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  297.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  298.     7.3.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  299.     7.3.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  300.     7.3.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  301.     7.3.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  302.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  303.     7.4.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  304.     7.4.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  305.     7.4.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  306.     7.4.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  307.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  308.     7.5.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  309.     7.5.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  310.     7.5.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  311.     7.5.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  312.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  313.     7.6.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  314.     7.6.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  315.     7.6.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  316.     7.6.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  317.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  318.     7.7.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  319.     7.7.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  320.     7.7.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  321.     7.7.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  322.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  323.     7.8.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  324.     7.8.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  325.     7.8.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  326.     7.8.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  327.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  328.     7.9.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  329.     7.9.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  330.     7.9.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  331.     7.9.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  332.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  333.     7.10.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  334.     7.10.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  335.     7.10.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  336.     7.10.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  337.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  338.     7.11.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  339.     7.11.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  340.     7.11.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  341.     7.11.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  342.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  343.     7.12.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  344.     7.12.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  345.     7.12.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  346.     7.12.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  347.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  348.     7.13.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  349.     7.13.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  350.     7.13.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  351.     7.13.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  352.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  353.     7.14.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  354.     7.14.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  355.     7.14.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  356.     7.14.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  357.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  358.     7.15.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  359.     7.15.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  360.     7.15.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  361.     7.15.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  362.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  363.     7.16.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  364.     7.16.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  365.     7.16.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  366.     7.16.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  367.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  368.     7.17.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  369.     7.17.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  370.     7.17.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  371.     7.17.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  372.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  373.     7.18.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  374.     7.18.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  375.     7.18.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  376.     7.18.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  377.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  378.     7.19.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  379.     7.19.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  380.     7.19.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  381.     7.19.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  382.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  383.     7.20.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  384.     7.20.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  385.     7.20.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  386.     7.20.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  387.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  388.     7.21.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  389.     7.21.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  390.     7.21.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  391.     7.21.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  392.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  393.     7.22.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  394.     7.22.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  395.     7.22.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  396.     7.22.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  397.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  398.     7.23.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  399.     7.23.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  400.     7.23.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  401.     7.23.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  402.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  403.     7.24.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  404.     7.24.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  405.     7.24.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  406.     7.24.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  407.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  408.     7.25.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  409.     7.25.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  410.     7.25.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  411.     7.25.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  412.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  413.     7.26.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  414.     7.26.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  415.     7.26.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  416.     7.26.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  417.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  418.     7.27.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  419.     7.27.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  420.     7.27.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  421.     7.27.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  422.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  423.     7.28.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  424.     7.28.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  425.     7.28.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  426.     7.28.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  427.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  428.     7.29.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  429.     7.29.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  430.     7.29.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  431.     7.29.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  432.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  433.     7.30.1 BY THERAPEUTIC TYPE, 2025-2035 (USD Billion)
  434.     7.30.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  435.     7.30.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
  436.     7.30.4 BY PATIENT TYPE, 2025-2035 (USD Billion)
  437.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  438.     7.31.1
  439.   7.32 ACQUISITION/PARTNERSHIP
  440.     7.32.1

Healthcare Market Segmentation

Healthcare By Therapeutic Type (USD Billion, 2025-2035)

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Radiation Therapy
  • Surgery

Healthcare By Drug Class (USD Billion, 2025-2035)

  • 5-Fluorouracil
  • Oxaliplatin
  • Bevacizumab
  • Cetuximab
  • Regorafenib

Healthcare By Route of Administration (USD Billion, 2025-2035)

  • Oral
  • Intravenous
  • Subcutaneous

Healthcare By Patient Type (USD Billion, 2025-2035)

  • Adult
  • Pediatric
  • Geriatric

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions